Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Bonesupport Holding AB (publ)

Healthcare US BOEUF

21.4USD
-1.39(6.10%)

Last update at 2026-06-22T14:07:00Z

Day Range

21.4021.40
LowHigh

52 Week Range

18.5735.00
LowHigh

Fundamentals

  • Previous Close 22.79
  • Market Cap2058.70M
  • Volume140
  • P/E Ratio123.91
  • Dividend Yield-%
  • EBITDA279.68M
  • Revenue TTM1119.12M
  • Revenue Per Share TTM17.00
  • Gross Profit TTM 1036.39M
  • Diluted EPS TTM0.23

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 199.02M 172.62M 15.75M -64.69400M -81.83700M
Minority interest - - - - -
Net income 141.80M 133.75M 245.02M -68.16700M -85.53100M
Selling general administrative 719.26M 98.99M 90.31M 73.31M 44.12M
Selling and marketing expenses - 510.35M 371.31M 238.45M 177.84M
Gross profit 1084.60M 832.25M 540.92M 297.71M 189.70M
Reconciled depreciation 7.74M 7.22M 10.07M 9.38M 8.28M
Ebit - 174.92M 18.86M -63.72400M -81.01700M
Ebitda 275.98M 185.75M 26.29M -54.34100M -72.74100M
Depreciation and amortization - 10.83M 7.43M 9.38M 8.28M
Non operating income net other - - - - -
Operating income 275.98M 166.15M 13.93M -64.53500M -80.66900M
Other operating expenses 895.74M 732.58M 577.15M 396.42M 297.46M
Interest expense 32.08M 2.29M 3.12M 0.97M 1.17M
Tax provision 57.36M 38.87M -229.27300M 3.47M 3.69M
Interest income 7.27M 8.77M 4.93M 0.81M 0.00000M
Net interest income -32.15700M 6.48M 1.82M -0.15900M -1.16800M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 57.22M 38.87M -229.27300M 3.47M 3.69M
Total revenue 1171.71M 898.73M 591.08M 328.82M 212.88M
Total operating expenses 808.62M 666.10M 526.99M 365.31M 274.28M
Cost of revenue 87.11M 66.48M 50.16M 31.11M 23.18M
Total other income expense net -76.95847M 6.48M 1.82M -0.15900M -1.16800M
Discontinued operations - - - - -
Net income from continuing ops 142.15M 133.75M 245.02M -68.16700M -85.53100M
Net income applicable to common shares - - - -68.16700M -85.53100M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 1033.54M 879.69M 688.82M 371.82M 343.92M
Intangible assets 14.91M 14.54M 4.04M 8.38M 8.37M
Earning assets - - - - -
Other current assets 57.98M 20.75M 35.72M 0.00100M -0.00100M
Total liab 168.46M 152.23M 143.64M 102.89M 78.22M
Total stockholder equity 865.08M 727.46M 545.18M 268.93M 265.70M
Deferred long term liab - - - 6.31M 5.97M
Other current liab 140.03M 106.70M 99.61M 61.52M 37.71M
Common stock 41.62M 41.73M 41.37M 41.36M 40.91M
Capital stock 41.73M 41.73M 41.37M 41.36M 40.91M
Retained earnings -726.77627M -886.77100M -1061.19400M -1344.67600M -1344.49400M
Other liab - - - 0.34M 0.36M
Good will - - - - -
Other assets - - - 6.31M 5.97M
Cash 377.04M 227.00M 166.93M 201.28M 206.46M
Cash and equivalents - - - - -
Total current liabilities 163.91M 144.19M 130.06M 90.20M 61.70M
Current deferred revenue - - 6.52M 55.18M 32.09M
Net debt -365.35680M -212.41500M -149.44500M -183.83000M -185.04200M
Short term debt 7.48M 6.93M 4.26M 5.10M 5.27M
Short long term debt - - - - -
Short long term debt total 11.68M 14.59M 17.48M 17.45M 21.42M
Other stockholder equity 1562.00M 1572.51M 1563.86M 1572.24M 1569.29M
Property plant equipment - - - 24.62M 27.08M
Total current assets 794.66M 622.60M 402.94M 338.81M 308.48M
Long term investments - - - - -
Net tangible assets - - - 266.85M 263.31M
Short term investments - - 0.42M - -
Net receivables 215.01M 240.73M 116.56M 81.22M 50.25M
Long term debt - - - - -
Inventory 144.63M 134.11M 83.30M 56.31M 51.76M
Accounts payable 16.40M 17.84M 19.66M 23.57M 18.72M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -11.76242M 6.58M 1.13M - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.00001M 0.43M 257.84M 0.00200M -0.00100M
Deferred long term asset charges - - - - -
Non current assets total 238.88M 257.10M 285.88M 33.01M 35.44M
Capital lease obligations 11.68M 14.59M 17.48M 17.45M 21.42M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -0.68500M -6.26500M -6.06000M -3.27900M -3.41600M
Change to liabilities - - - 0.00000M 0.00000M
Total cashflows from investing activities -5.86525M -6.26500M -6.06000M -3.27900M -3.41600M
Net borrowings - - - -8.13200M -5.50900M
Total cash from financing activities -57.89141M -4.75200M -6.70300M 42.78M -61.56100M
Change to operating activities - - - 24.06M 0.96M
Net income 141.80M 166.15M 245.02M -64.53500M -80.66900M
Change in cash 188.69M 59.65M -33.93000M -5.18300M -147.27300M
Begin period cash flow 188.35M 167.35M 201.28M 206.46M 353.74M
End period cash flow 377.04M 227.00M 167.35M 201.28M 206.46M
Total cash from operating activities 220.75M 65.70M -18.25700M -46.98500M -83.42100M
Issuance of capital stock 0.00000M 2.42M 0.03M 50.91M 6.28M
Depreciation 7.74M 7.22M 7.43M 9.38M 8.28M
Other cashflows from investing activities - -4.31000M -5.24000M - -
Dividends paid - - - - -
Change to inventory -60.78400M -21.99900M -37.43300M 7.08M -0.11700M
Change to account receivables - -95.38900M -77.61900M -25.98200M -5.42100M
Sale purchase of stock -16.25000M 0.00000M - - -62.33300M
Other cashflows from financing activities -57.83355M -0.20400M -0.16300M -8.13200M -5.50900M
Change to netincome - - - 6.64M -1.58600M
Capital expenditures 2.56M 5.84M 6.06M 3.28M 3.42M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -68.83089M -92.56300M -97.69100M 5.16M -4.58000M
Stock based compensation 32.31M 15.89M 39.92M 17.89M 7.37M
Other non cash items 147.78M -30.98900M -212.92900M -14.88000M -13.81300M
Free cash flow 218.19M 59.86M -24.31700M -50.26400M -86.83700M

Peer Comparison

Sector: Healthcare Industry: Medical Instruments & Supplies

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
BOEUF
Bonesupport Holding AB (publ)		 -1.39 6.10% 21.40 123.91 - 14.86 19.84 14.47 79.25
ISRG
Intuitive Surgical Inc		 -3.83 0.94% 402.95 73.05 61.73 19.15 10.25 18.41 59.92
ESLOF
EssilorLuxottica Société anonyme		 -13.86 6.73% 192.00 44.84 27.62 4.07 2.49 3.71 16.04
ESLOY
Essilor International SA		 -5.56 5.46% 96.36 41.68 27.25 3.94 2.45 3.71 16.04
BDX
Becton Dickinson and Company		 -3.27 2.27% 140.71 25.56 12.48 2.59 1.76 2.89 12.55

Reports Covered

Stock Research & News

View All

Profile

Bonesupport Holding AB (publ), an orthobiologics company, develops and sells injectable bio-ceramic bone graft substitutes in Europe, North America, and internationally. The company provides CERAMENT Bone Void Filler, an injectable ceramic bone graft substitute that remodels to host bone; CERAMENT G, an injectable ceramic bone graft substitute that remodels to host bone and elutes Gentamicin during the critical first 30 days of bone healing, as well as treats and prevents bone infection; CERAMENT V, an injectable ceramic bone graft substitute that remodels to host bone and elutes Vancomycin during the critical first 30 days of bone healing, as well as treats and prevents bone infection. It also offers CERAMENT Bead Tray, an adjunctive local delivery option for surgeons for targeted delivery to osseous defects and for dead space management. In addition, the company develops preclinical product candidates to promote bone regrowth focusing on trauma, revision arthroplasty, chronic osteomyelitis, and foot and ankle surgery. Bonesupport Holding AB (publ) was founded in 1999 and is headquartered in Lund, Sweden.

Bonesupport Holding AB (publ)

Scheelevägen 19, Lund, Sweden, 223 70

Key Executives

Name Title Year Born
Mr. Emil Billbäck Chief Exec. Officer 1970
Prof. Lars A. Lidgren M.D., Ph.D. Founder & Director 1943
Mr. Håkan Johansson Chief Financial Officer 1963
Ms. Ann-Marie Thor Acting Exec. VP of Global Marketing NA
Ms. Helena L. Brandt Head of HR 1965
Dr. Michael Diefenbeck M.D., Ph.D. Exec. VP of Medical & Clinical Affairs and Chief Medical Officer 1974
Dr. Jerry Chang Exec. VP of R&D, Regulatory and Clinical 1959
Mr. Fergus MacLeod GM & Exec. VP of Commercial Operations of EUROW 1970
Ms. Kristina Ingvar Exec. VP of Quality Management & Regulatory Affairs 1972
Mr. Michael Roth GM & Exec. VP of Commercial Operations of North America 1963

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions